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PURPOSE. We describe the differences and similarities in clinical characteristics and phenotype
of familial and sporadic patients with age-related macular degeneration (AMD).
METHODS. We evaluated data of 1828 AMD patients and 1715 controls enrolled in the
European Genetic Database. All subjects underwent ophthalmologic examination, including
visual acuity testing and fundus photography. Images were graded and fundus photographs
were used for automatic drusen quantification by a machine learning algorithm. Data on
disease characteristics, family history, medical history, and lifestyle habits were obtained by a
questionnaire.
RESULTS. The age at first symptoms was significantly lower in AMD patients with a positive
family history (68.5 years) than in those with no family history (71.6 years, P ¼ 1.9 3 105).
Risk factors identified in sporadic and familial subjects were increasing age (odds ratio [OR],
1.08 per year; P ¼ 3.0 3 1051, and OR, 1.15; P ¼ 5.3 3 1036, respectively) and smoking
(OR, 1.01 per pack year; P ¼ 1.1 3 106 and OR, 1.02; P ¼ 0.005). Physical activity and
daily red meat consumption were significantly associated with AMD in sporadic subjects
only (OR, 0.49; P ¼ 3.7 3 1010 and OR, 1.81; P ¼ 0.001). With regard to the phenotype,
geographic atrophy and cuticular drusen were significantly more prevalent in familial AMD
(17.5% and 21.7%, respectively) compared to sporadic AMD (9.8% and 12.1%).
CONCLUSIONS. Familial AMD patients become symptomatic at a younger age. The higher
prevalence of geographic atrophy and cuticular drusen in the familial AMD cases may be
explained by the contribution of additional genetic factors segregating within families.
Keywords: AMD, family history, clinical characteristics
Age-related macular degeneration (AMD) is a multifactorialretinal disease leading to severe vision loss among the
elderly. Advanced age, female sex, smoking, and obesity (body
mass index [BMI] > 30) are most commonly reported as
important demographic and environmental risk factors for the
development of AMD.1–6 In addition, several important
genetic variants have been found to be associated with
AMD, either as a risk factor or as a protective factor. The
strongest associations have been reported for the single-
nucleotide polymorphisms (SNPs) in the complement factor H
gene (CFH Y402H; rs1061170), and in the age-related
maculopathy susceptibil i ty 2 gene (ARMS2 A69S;
rs10490924), which strongly increase the risk of developing
AMD.7–11
Previous studies have demonstrated aggregation of AMD
in families.12,13 A family history of AMD has been reported as
a significant risk factor for AMD.14 Individuals are at a higher
risk of developing AMD when a first-degree relative is
affected. Moreover, having an affected parent is associated
with a higher risk than having an affected sibling.13,14 Shahid
et al.14 showed an odds ratio (OR) for AMD of 27.8 in people
with an affected parent and 12.0 for people with an affected
sibling. Likewise, Luo et al.13 reported a relative risk for the
development of AMD of 5.66 for people with an affected
parent and 2.95 for people with an affected sibling.
A lower age at onset has been reported in familial AMD
patients and heritability of AMD subtypes has been suggest-
ed.14,15 Even though environmental and genetic risk factors
can cluster in families, the number of affected family
members in large densely affected families cannot be fully
explained by clustering of known risk factors.12 Several
recent studies have shown that rare, highly penetrant genetic
variants can strongly increase the risk of developing AMD in
families with AMD, as well as in the AMD population in
general.16–20
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Little is known about clinical differences and similarities
between patients with and without a family history for AMD.
The purpose of this study is to gain more insight into the
clinical and phenotypic characteristics of familial and sporadic
AMD patients, and to analyze if there are distinct clinical
differences between these subgroups.
PATIENTS AND METHODS
Study Population
The European Genetic Database (EUGENDA, available in the
public domain at www.eugenda.org) is a multicenter database
for clinical and molecular analysis of AMD founded by the
Radboud University Medical Center (Nijmegen, the Nether-
lands) and the Department of Ophthalmology of the University
Hospital of Cologne (Cologne, Germany). This database
contains data of AMD patients and control individuals,
including family history, environmental risk factors, and
ophthalmologic examination. For this retrospective study we
evaluated data of 1828 Caucasian patients with AMD and 1715
Caucasian controls enrolled in EUGENDA of whom family
history of AMD, smoking status, BMI, age, and sex data were
available.
This study was performed in accordance with the tenets
of the Declaration of Helsinki and was approved by the local
ethical committees at the Radboud University Medical Center
and the University of Cologne. Written informed consent
was obtained from all participants before enrolling in
EUGENDA.
Questionnaire, Clinical Evaluation, and Grading
Before enrollment in the EUGENDA database, all subjects
were interviewed with a detailed questionnaire about
disease characteristics (e.g., age at first symptoms), family
history, medical history, and lifestyle habits, such as smoking
status, diet, and physical activity. For each subject, BMI was
calculated using body height and body weight as reported in
the questionnaire. Based on years of smoking and number of
cigarettes smoked per day, we calculated the number of
pack years. Each subject underwent an ophthalmologic
examination, including Early Treatment Diabetic Retinopathy
Study (ETDRS) visual acuity testing, dilated fundus examina-
tion, and color fundus photography. The best corrected
visual acuity (BCVA) was converted to logMAR visual acuity
for the purpose of statistical analysis. Two independent
certified reading center graders evaluated color fundus
photographs of both eyes of all subjects according to the
standard protocol of the Cologne Image Reading Center and
Laboratory (CIRCL).21 Digital nonstereoscopic 308 color
fundus photographs centered on the fovea were performed
with a Topcon TRC 50IX camera (Topcon Corporation,
Tokyo, Japan). The diagnosis and grading of AMD was based
on a classification and grading scheme as described
previously.22 For all analyses in this study we used the
grading of the worst affected eye, and subjects with only
one gradable color fundus photograph were excluded.
Additionally, in 1184 AMD subjects spectral-domain optical
coherence tomography (SD-OCT, Spectralis; Heidelberg
Engineering, Heidelberg, Germany) was available and eval-
uated for the presence of reticular pseudodrusen. In 677
subjects the presence of cuticular drusen was evaluated
based on available fluorescein angiography, performed using
the Spectralis HRA system (Heidelberg Engineering).23 The
SD-OCT volume scans consisting of 19 or 37 parallel OCT B-
scans were used for analysis, covering 6 3 4 mm of the
macula. For each OCT B-scan, 20 images were averaged
using the automated real-time function.21 Evaluation of the
presence of reticular pseudodrusen on SD-OCT and cuticular
drusen on fluorescein angiography was done by one senior
grader.
Based on diagnosis and family history, the participants in
this study were divided into four groups: sporadic AMD,
sporadic control, familial AMD, and familial control. We
classified subjects as familial in case of confirmed or possible
AMD in at least one close relative, defined as a parent, sibling,
or child. Sporadic subjects were defined as individuals who did
not have a close relative with AMD.
Automatic Drusen Quantification
In addition to the human grading of AMD based on
photographs, a machine learning algorithm for computer-
aided diagnosis of AMD was used for detection and
quantification of drusen number and area (measured in
pixels). This was described previously as accurate in
detecting and quantifying drusen number and area on color
fundus photographs of patients with nonadvanced AMD and
control subjects.24 Patients with advanced AMD in the worst
affected eye have been excluded for this specific analysis,
because the automatic system was not designed to deal with
images containing signs of advanced stage AMD. A quality
score ranging from 0 to 1 was calculated, with 0 being the
worst quality and 1 being the best quality. Only color fundus
photographs were selected with a quality score of 0.3 or
more, which corresponds to sufficient quality for human
grading.
Statistical Analysis
All statistical analyses were performed using IBM SPSS Statistics
software, version 20.0 (Released 2011; IBM Corp., Armonk,
NY, USA). Each potential risk factor for the development of
AMD obtained from the questionnaire was included separately
in a logistic regression analysis adjusted for age, sex, smoking,
and BMI. The ORs were calculated for familial subjects (familial
AMD versus familial controls) and sporadic subjects (sporadic
AMD versus sporadic controls). Significant differences be-
tween ORs for sporadic and familial subjects were identified by
interaction analysis using binary logistic regressions. All
continuous variables were analyzed using an independent
sample t-test or 1-way ANOVA. An univariate general linear
model was used when continuous variables were analyzed
with correction for other variables. Categorical variables were
analyzed using a v2 test. Differences with a P value less than
0.05 were considered statistically significant. Because multiple
possible risk factors were analyzed and many tests of
significance were performed in our study, Bonferroni correc-
tion was performed for the risk and interaction analysis of
environmental factors.
RESULTS
Demographic characteristics of the cohort are shown in Table
1. All four groups were comparable for sex, smoking, and BMI.
The mean age of the familial subjects was slightly lower than in
sporadic subjects (69.6 and 73.0 years, respectively; P¼ 4.73
1016), mainly due to younger familial control individuals. In
309 subjects who reported in the questionnaire to have a close
relative with (possible) AMD, the ophthalmologically examined
AMD status of close relatives was available. To determine the
degree of misclassification of subjects into familial or sporadic
based on the questionnaire, we compared the family history to
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these examined data. In 3 of 309 cases where subjects reported
in the questionnaire to have at least one close relative with
AMD, no family members seemed to be affected upon
ophthalmological examination. Therefore, these cases were
incorrectly classified as familial. No ophthalmological informa-
tion was available for relatives of sporadic subjects included in
this study.
Familial and Sporadic AMD: Clinical Differences
and Similarities
Information about the age at first symptoms was available in
703 AMD patients (469 sporadic subjects, 234 familial
subjects, Table 2). The age at first symptoms was significantly
lower (P ¼ 1.9 3 105) in familial AMD patients (mean, 68.5
years; SD, 9.8) than in sporadic AMD patients (mean, 71.6
years; SD, 8.7) with a mean difference of 3.1 years (95%
confidence interval [CI], 1.7–4.5). When subdividing AMD in
the presence or absence of the reticular pseudodrusen
subtype, the age at first symptoms was also lower in familial
AMD patients. In addition, AMD patients with reticular
pseudodrusen have a significantly higher age at first symp-
toms than patients without reticular pseudodrusen, in
sporadic and familial patients (P ¼ 4.4 3 1010 and P ¼
0.002, respectively). In contrast, in AMD patients with the
cuticular drusen subtype, the age at first symptoms was lower
than in patients without cuticular drusen, in sporadic and
familial patients (P¼ 1.263 106 and P¼ 0.074, respectively).
However, no significant difference in age at first symptoms
was observed between familial and sporadic patients with the
cuticular drusen subtype (P ¼ 0.740).
Despite a younger age at first symptoms, BCVA of both eyes
did not differ significantly between familial and sporadic AMD
patients when subdivided in three age categories (data shown
in Table 2). Also, if young patients (<60 years) were analyzed
separately, no difference in BCVA was observed between
familial and sporadic patients (data not shown). After
distinguishing between advanced and nonadvanced AMD
subjects, BCVA also was comparable between sporadic and
familial patients.
To identify risk factors in our cohort, we analyzed several
demographic and environmental factors (Table 3). Risk factors
identified in sporadic and familial AMD patients were
increasing age (P ¼ 3.0 3 1051 and P ¼ 5.3 3 1036) and
smoking (P ¼ 1.1 3 106 and P ¼ 0.005). Interaction analysis
showed a significant difference between sporadic and familial
subjects for increasing age (P ¼ 9.4 3 107).
In terms of comorbidity (Table 3), allergy was significantly
associated with a decreased risk of AMD for sporadic and
familial subjects (P ¼ 0.002 and P ¼ 0.024, respectively).
Diabetes mellitus was a risk factor for the development of
AMD in sporadic patients (OR, 1.34; 95% CI, 1.02–1.75; P ¼
0.035), but not in familial cases (P ¼ 0.704). No significant
interaction between family history and allergy or diabetes was
present. Cardiovascular disease, renal disease, and autoim-
mune disease were no significant risk factors for AMD in our
cohort.
With regard to dietary factors, we observed that eating red
meat a few times per week or daily is a significant risk factor in
sporadic AMD patients (OR, 1.24; 95% CI, 1.05–1.48; P¼0.013
and OR, 1.81; 95% CI, 1.30–2.54; P¼ 0.001, respectively), but
not in familial subjects. A protective factor for AMD in sporadic
patients was eating fruit a few times per week (OR, 0.60; 95%
CI, 0.40–0.90; P¼0.013). Intake of fruit every day did not seem
to further decrease the risk of AMD (OR, 0.74; 95% CI, 0.52–
1.04; P ¼ 0.085). However, consumption of fruit was not
significantly associated with a decreased risk of AMD in familial
subjects.
Regular physical activity, one or two times a week, was
significantly associated with a decreased risk for AMD in the
sporadic AMD subgroup (OR, 0.67; 95% CI, 0.56–0.81; P¼ 2.6
3 106) and the familial AMD subgroup (OR, 0.62; 95% CI,
0.42–0.94; P ¼ 0.022).
After Bonferroni correction of the demographic and
environmental risk factors for AMD, the association of
increasing age with AMD in familial and sporadic subjects
remained significant, as well as the association of female sex,
TABLE 1. Demographic Characteristics
Sporadic Familial
AMD Control Total AMD Control Total
Cases, n 1330 1405 2735 498 310 808
Sex, n (%)
Male 536 (40.3) 587 (41.8) 1123 (41.1) 181 (36.3) 132 (42.6) 313 (38.7)
Female 794 (59.7) 818 (58.2) 1612 (58.9) 317 (63.7) 178 (57.4) 495 (61.3)
Age, mean 6 SD* 75.6 6 9.1 70.5 6 7.3 73.0 6 8.6 74.0 6 8.4 62.6 6 10.2 69.6 6 10.7
Smoking, mean 6 SD† 14.6 6 20.1 11.6 6 16.6 13.1 6 18.4 14.5 6 17.9 12.2 6 15.9 13.6 6 17.2
BMI, n (%)
<25 600 (45.1) 638 (45.4) 1238 (45.2) 233 (46.8) 139 (44.8) 372 (46.0)
25–30 558 (42.0) 599 (42.6) 1157 (42.3) 208 (41.8) 124 (40.0) 332 (41.1)
>30 172 (12.9) 168 (12.0) 340 (12.4) 57 (11.4) 47 (15.2) 104 (12.9)
Examined family history, n (%) 165 (100) 144 (100) 309 (100)
Familial 164 (99.4) 142 (98.6) 306 (99.0)
Sporadic 1 (0.6) 2 (1.4) 3 (1.0)
The study included 498 familial AMD patients deriving from 393 families (393 probands and 105 family members) and 310 controls deriving
from 216 families (216 probands and 94 family members). In 309 familial cases information about ophthalmologic examination in their close
relatives (parents, sibling, and/or children) was available and was compared to family history based on the questionnaire to determine the degree of
misclassification. Familial, positive family history for AMD (confirmed or possible AMD in at least one close relative [parent, sibling or child]);
sporadic, no positive family history.
* Age of participation in years.
† Smoking in pack years.
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smoking, allergy, daily red meat consumption and physical
activity in sporadic patients only.
Familial and Sporadic AMD: Phenotypic
Differences and Similarities
The prevalence of early, intermediate, and advanced stage
AMD was similar in the familial and sporadic AMD patient
group (Table 2). After differentiation of advanced AMD into
geographic atrophy (GA), choroidal neovascularization
(CNV), and mixed (GA and CNV in one patient), we found
that GA was more prevalent in familial AMD patients (17.5%)
than in sporadic AMD patients (9.8%, P¼ 3.03 104), despite
a comparable SNP load of CFH Y402H and ARMS2 A69S
between familial (n¼ 51) and sporadic patients (n¼ 58) with
GA (data not shown). In 829 sporadic subjects and 355
familial subjects data on reticular pseudodrusen were
available, and data on cuticular drusen were available in
520 sporadic and 157 familial subjects. The prevalence of
reticular pseudodrusen was comparable between familial
(18.0%) and sporadic subjects (18.8%, P ¼ 0.749), whereas
the prevalence of cuticular drusen was significantly higher in
familial AMD (21.7%) compared to sporadic AMD (12.1%, P¼
0.003).
Data on the number of drusen and area of drusen within the
macular area were available for 689 sporadic subjects and 203
familial subjects (Table 4). Familial subjects showed a trend
toward a higher number of drusen and a larger area of drusen
in the macula compared to sporadic patients, although this was
only significant for the area of drusen in subjects with
intermediate AMD (P ¼ 0.043). After correction for age, sex,
BMI, and smoking, the mean area of drusen in sporadic
subjects with intermediate AMD was 1114.49 and 1415.63 in
familial subjects, which were no longer significantly different
(P ¼ 0.160).
DISCUSSION
Familial and Sporadic AMD: Clinical Differences
and Similarities
Familial AMD patients have a lower age at first symptoms
compared to sporadic AMD patients. The phenomenon of a
lower age at onset in patients with familial occurrence has
been shown in other complex diseases with a significant
genetic component, such as schizophrenia and Alzheimer’s
disease.25,26 A lower age at onset in familial AMD patients has
previously been reported by Shahid et al.14 (70.4 years in
familial patients and 73.2 years in sporadic patients), and is in
accordance with the mean difference of 3.1 years in our study.
A significant difference in age of onset between familial and
sporadic subjects also was observed in AMD patients with
reticular pseudodrusen, but not in patients with cuticular
drusen. However, as a result of a positive family history, familial
subjects may have an increased awareness of visual symptoms
which can lead to an earlier visit at a physician for evaluation.
Therefore, it should be noted that the lower age at first
symptoms in familial AMD patients may be partially attributed
to an ascertainment bias.
In our study, BCVA per age category did not differ
between familial and sporadic AMD patients, suggesting that
visual acuity does not decrease earlier or at a faster rate in
familial patients, despite the lower age at first symptoms in
familial AMD patients. Heightened awareness in familial
patients may explain why no actual difference in BCVA was
observed.
Similar to other studies,1–3,6 smoking and advanced age
were associated with the development of AMD in the current
study, in sporadic and familial subjects. Furthermore, age was a
more important risk factor for AMD in familial subjects as age
shows a significant interaction with family history, resulting in
a younger age at onset in familial subjects.
TABLE 2. Clinical Features and Staging of Sporadic and Familial AMD Patients
Sporadic AMD
Mean 6 SD
Familial AMD
Mean 6 SD P
Age at first symptoms, y
AMD, total* 71.6 6 8.7 68.5 6 9.8 1.9 3 105
AMD, reticular pseudodrusen† 76.2 6 7.2 72.5 6 7.3 0.008
AMD, cuticular drusen‡ 65.8 6 9.2 64.5 6 17.7 0.740
Visual acuity per age category§
<70 0.12 6 0.27 0.09 6 0.25 0.293
70–80 0.19 6 0.29 0.26 6 0.36 0.107
>80 0.40 6 0.40 0.38 6 0.46 0.814
Visual acuity per stage§
Nonadvanced 0.05 6 0.14 0.03 6 0.13 0.367
Advanced 0.33 6 0.37 0.37 6 0.42 0.314
Grading, n (%)
Early 301 (22.6) 94 (18.9) 0.158
Intermediate 250 (18.8) 90 (18.1)
Advanced 779 (58.6) 314 (63.1)
GA 76 (9.8) 55 (17.5) 3.0 3 104
CNV 660 (84.7) 234 (74.5)
Mixed 43 (5.5) 25 (8.0)
* Data on age of first symptoms were available in 469 sporadic and 234 familial AMD patients.
† Data on age of first symptoms were available in 75 sporadic and 45 familial AMD patients with reticular pseudodrusen.
‡ Data on age of first symptoms were available in 32 sporadic and 19 familial AMD patients with cuticular drusen.
§ Visual acuity defined as best-corrected logMAR visual acuity.
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Ristau et al.22 have reported recently that allergy is
associated with a reduced risk of AMD. We did not find a
significant difference for the association of allergy with AMD
between familial and sporadic subjects, so the protective
effect of allergy does not seem to be influenced by family
history.
The pathogenesis of AMD as well as cardiovascular disease
and diabetes have been linked to oxidative stress, inflamma-
tion and a vascular origin. Moreover, diabetes, cardiovascular
disease, and its risk factors have been associated with the
development of AMD, although this was not consistent
among studies.1,27–30 In the current study we observed that
sporadic subjects with diabetes have an increased risk for
AMD. However, diabetes was no risk factor for familial AMD,
which may be explained by the larger genetic component in
the pathophysiology of familial AMD, while sporadic AMD
may be associated with a larger contribution of environmen-
tal or lifestyle factors, such as diabetes (and associated
factors).
Several studies reported an increased risk of AMD for
patients with chronic renal disease.31,32 It has been shown that
AMD and renal diseases, such as membranoproliferative
glomerulonephritis type 2 and atypical hemolytic uremic
syndrome, are related to the same genetic variants of the
complement pathway, including the complement factor H
gene.33–35 Therefore, we evaluated whether renal disease
might be correlated with AMD in familial subjects. However,
we did not find a clear association between familial AMD and
renal disease in our study population, possibly due to the low
number of patients with renal disease.
We also compared dietary factors between familial and
sporadic subjects. It is interesting to investigate these dietary
factors, since these are modifiable. The consumption of red
meat at least a few times a week increased the risk of AMD in
our sporadic patient cohort. This is supported by findings of
Chong et al.,36 demonstrating that higher red meat intake was
associated with the development of AMD. In our study
consumption of fruit a few times a week was associated with
a decreased risk for the development of AMD, but we did not
observe such an association with frequent consumption of
vegetables. In agreement with this finding, Cho et al.37 and
Zerbib et al.38 described a protective effect of frequent
consumption of fruits for exudative AMD, but no association
with the consumption of vegetables. A study by Seddon et al.39
showed that intake of foods rich in carotenoids, in particular
green leafy vegetables, decreased the risk of exudative AMD.
Our study might be limited because we did not discriminate
between different kinds of vegetables and no risk calculation
was performed for the progression to advanced AMD. This may
explain why we did not observe a protective effect for the
consumption of vegetables. Also, it must be considered that
fruit consumption can be related to a more healthy lifestyle in
general, and, therefore, these results may be confounded by
other factors, other than smoking and BMI, related to a healthy
lifestyle.
In cuticular drusen, a clinical subtype of AMD that tends to
cluster in families, differences in environmental and genetic
risk factors have been reported compared to the AMD group as
a whole.23,40 We previously reported that the association with
smoking was significantly lower in patients with cuticular
drusen compared to AMD patients without cuticular drusen.23
In this study, we observed no significant difference in
environmental risk factors, such as smoking, between familial
and sporadic AMD. However, several factors, such as the
consumption of red meat and frequent physical activity, tended
to have a less important role in familial AMD than in sporadic
AMD, supporting a stronger genetic component in the
pathophysiology of AMD in families.
Familial and Sporadic AMD: Phenotypic
Differences and Similarities
In our study population, GA was more prevalent in familial
AMD patients than in sporadic patients. This cannot be
explained by selection bias of familial patients, because if
only the probands of the familial group (n ¼ 262) were
included in the analysis, GA was still significantly more
prevalent in the familial AMD group than in the sporadic
group (17.6% and 9.8%, respectively, P¼ 0.001). This finding
may be explained by the stronger influence of genetic
factors in the pathogenesis of familial AMD in certain
phenotypic subtypes, such as GA. Previously Shahid et
al.14 suggested heritability of AMD subtypes, but these
investigators were not able to confirm this hypothesis due to
low numbers of subjects. Sobrin et al.15 showed that siblings
are more likely to develop the same advanced subtype as
their proband. This may suggest the contribution of genetic
variants in these familial patients,16,35,41 which may increase
the risk for developing GA rather than CNV. Affected
members of densely affected families have been reported
to bear a lower SNP load than expected based on five
common known AMD risk variants; CFH (rs1061170 and
rs1410996), ARMS2 (rs10490924), C2-CFB (rs641153 and
rs9332739).10 This supports the hypothesis that rare genetic
variants in these families may explain the high prevalence of
AMD.
In this study, we reported a higher prevalence of cuticular
drusen in familial AMD compared to sporadic AMD, which is in
agreement with previous reports.40,42,43 However, in our
cohort the prevalence of cuticular drusen was higher and
32% of the patients with cuticular drusen had a positive family
history of AMD compared to 44% of the patients in a study of
Grassi et al.40 Previously, our group demonstrated that
heterozygous loss-of-function mutations in the CFH gene are
found among family members with cuticular drusen.35,41 In
addition, rare highly penetrant variants in the CFI gene have
been identified in patients with cuticular drusen.16,44 There-
fore, the higher prevalence of cuticular drusen in families may
be explained by segregation of rare, highly penetrant variants
within these families.
In addition to a possible ascertainment bias, caused by an
increased awareness of disease-associated visual symptoms in
familial subjects, another limitation of this study is the
classification of subjects into familial or sporadic based on
the family history in the questionnaire, which may lead to
misclassification. However, in a subset of the familial cases
TABLE 4. Number and Area of Drusen in Sporadic and Familial Control
Individuals and Nonadvanced AMD Patients
Sporadic Familial
Pn Mean 6 SD n Mean 6 SD
Control
Drusen, n 159 2.25 6 6.0 24 2.85 6 3.4 0.633
Drusen area* 159 81.65 6 149.6 24 128.86 6 129.5 0.145
Early
Drusen, n 291 8.69 6 20.0 93 11.69 6 27.37 0.254
Drusen area* 291 219.17 6 353.4 93 249.67 6 416.6 0.489
Intermediate
Drusen, n 239 40.25 6 62.4 86 46.37 6 48.9 0.411
Drusen area* 239 1167.90 6 1735.4 86 1598.70 6 1555.4 0.043
* Area of drusen in pixels.
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ophthalmologic examination data of their close relatives were
available and compared to our classification based on the
family history of the questionnaire. The degree of misclassifi-
cation of the family history was very low in the familial
subjects, as in only three cases (1.0%) no close relative with
AMD was found by ophthalmologic examination. Unfortunate-
ly, no clinical data of family members of sporadic cases were
available. The rate of misclassification may be higher in
sporadic individuals, as these subjects may not have been
informed of the eye disease of close relatives or the relatives
were asymptomatic and therefore, not yet diagnosed with
AMD.
In conclusion, this study demonstrated that familial AMD
patients have a lower age at first symptoms compared to
sporadic patients. Our findings also indicate that familial AMD
patients differ from sporadic patients in terms of risk factors
and clinical features. The higher prevalence of GA and
cuticular drusen in familial AMD patients may be explained
by the contribution of additional genetic factors segregating
within these families.
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